710 Safety and survival results from a phase 1/2 trial of intratumoral agent INT230–6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers

Autor:	Jacob Thomas, Anthony El-Khoueiry, Diana Hanna, Anthony Olszanski, Nilofer Azad, Giles Whalen, Matthew Ingham, Luis Camacho, Franco Abbate, Lewis Bender, Ian Walters, Lillian Siu
Rok vydání:	2022
Zdroj:	Regular and Young Investigator Award Abstracts.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a8477db3b722ae99187b9b0bdac57fe8 https://doi.org/10.1136/jitc-2022-sitc2022.0710 Zobrazit plný text záznamu